Page last updated: 2024-11-04

disopyramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Disopyramide is a class Ia antiarrhythmic drug that was first synthesized in 1960. It is used to treat ventricular tachycardia and fibrillation. Disopyramide works by blocking sodium channels in the heart, which slows down the rate at which electrical impulses travel through the heart. This can help to prevent abnormal heart rhythms. Disopyramide has also been studied for its potential to treat other conditions, such as Parkinson's disease and Alzheimer's disease, but it is not currently approved for these uses.'

Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3114
CHEMBL ID517
CHEBI ID4657
SCHEMBL ID16153
SCHEMBL ID23931452
MeSH IDM0006581

Synonyms (173)

Synonym
AC-16018
BRD-A29734509-001-03-8
BRD-A29734509-011-02-9
2-pyridineacetamide, .alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-
KBIO1_000489
DIVK1C_000489
EU-0100402
SPECTRUM_001008
PRESTWICK3_000266
PRESTWICK_681
ritmilen
diisopyramide
SPECTRUM5_000943
BPBIO1_000124
LOPAC0_000411
IDI1_000489
BSPBIO_001928
BSPBIO_000112
LOPAC0_000402
CHEBI:4657 ,
4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide
disopyramidum
disopiramida
AB00053462
C06965
3737-09-5
disopyramide
DB00280
D00303
disopyramide (jp17/usan/inn)
rythmodan p (tn)
einecs 223-110-2
gamma-diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide
disopiramida [inn-spanish]
alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide
searle 703
dicorantil
2-pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-
ritmodan
h 3292
sc 7031
2-pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-
disopyramidum [inn-latin]
KBIO2_001488
KBIOSS_001488
KBIO2_006624
KBIOGR_001127
KBIO2_004056
KBIO3_001148
PRESTWICK1_000266
SPECTRUM3_000404
SPBIO_002331
SPBIO_001245
SPECTRUM4_000524
NINDS_000489
PRESTWICK0_000266
SPECTRUM2_001033
PRESTWICK2_000266
NCGC00093829-03
NCGC00093829-01
NCGC00093829-02
NCGC00015358-04
alpha-diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide
D 7644 ,
NCGC00015358-08
NCGC00015358-09
MLS002222242
smr001307254
rythmodan p
(rs)-disopyramide
CHEMBL517 ,
h-3292
isorythm
disopiramide
dl-disopyramide
lispine
searle-703
sc-7031
FT-0667714
HMS1568F14
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
bdbm50028893
HMS3261A06
HMS2095F14
tox21_110727
cas-3737-09-5
dtxcid9025536
dtxsid1045536 ,
disopyramide free base
CCG-204495
HMS2234G08
NCGC00015358-05
NCGC00015358-06
NCGC00015358-13
NCGC00015358-14
NCGC00015358-15
NCGC00015358-10
NCGC00015358-12
NCGC00015358-11
gfo928u8mq ,
disopyramide [usan:inn:ban:jan]
unii-gfo928u8mq
LP00402
AKOS015894712
S5490
gtpl7167
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanimidic acid
HMS3369O21
disopyramide [usan]
4-diisopropylamino-2-phenyl-2-(2-pyridyl)butyramide
(+/-)-disopyramide
disopyramide [ep monograph]
2-pyridineacetamide, .alpha.-(2-(bis(1-methylethyl)amino)ethyl)-.alpha.-phenyl-
disopyramide [inn]
disopyramide [vandf]
disopyramide [mi]
74427-45-5
alpha-[2-(diisopropylamino)ethyl]-alpha-phenyl-2-pyridineacetamide
disopyramide [mart.]
disopyramide [who-dd]
disopyramide [jan]
SCHEMBL16153
NCGC00015358-18
tox21_110727_1
NCGC00261087-01
tox21_500402
4-(diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide
racemic 2-phenyl-2-(2-pyridyl)-4-[n,n-bis(1-methylethyl)amino]butanamide
1216989-88-6
4-(diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide #
2-pyridineacetamide, .alpha.-[2-(diisopropylamino)ethyl]-.alpha.-phenyl-
.gamma.-diisopropylamino-.alpha.-phenyl-.alpha.-(2-pyridyl)butyramide
sc 13957 (salt/mix)
.alpha.-(2-(diisopropylamino)ethyl)-.alpha.-phenyl-2-pyridineacetamide
4-diisopropylamino-2-phenyl-2-(2-pyridyl)-butyramide
norpace (salt/mix)
4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butyramide
D2793
AB00053462_16
AB00053462_17
mfcd00057366
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide
SR-01000003039-3
disopyramide, european pharmacopoeia (ep) reference standard
disopyramide 1.0 mg/ml in methanol
SR-01000003039-10
SBI-0050388.P005
NCGC00015358-19
HMS3712F14
4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide
Q425120
Z1556052559
BS-17145
HY-12533
BRD-A29734509-011-06-0
SDCCGSBI-0050388.P006
HMS3886E08
NCGC00015358-24
NCGC00015358-25
CS-0011990
T70845
3737-09-5 (free base)
alpha-[2-[bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridineacetamide
nsc791109
nsc-791109
SCHEMBL23931452
SY052319
(2rs)- 4-bis(1-methylethyl)amino-2-phenyl-2-(pyridin-2-yl)butanamide
disopyramide (mart.)
disopyramide (ep monograph)
disopiramida (inn-spanish)
c01ba03
disopyramidum (inn-latin)

Research Excerpts

Overview

Disopyramide is a sodium channel blocker with negative inotropic properties that effectively reduces left ventricular outflow tract gradients in adults with hypertrophic cardiomyopathy. Its efficacy in children is uncertain. It is an effective class I antiarrhythmic drug and widely used for the treatment of arrhythmias.

ExcerptReferenceRelevance
"Disopyramide is a safe and effective treatment for LVOTO-related symptoms in childhood obstructive HCM. "( Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy.
Boleti, O; Cervi, E; Field, E; Kaski, JP; Norrish, G; Topriceanu, CC, 2023
)
3.8
"Disopyramide is a sodium channel blocker with negative inotropic properties that effectively reduces left ventricular outflow tract gradients in adults with hypertrophic cardiomyopathy, but its efficacy in children is uncertain."( Disopyramide use in infants and children with hypertrophic cardiomyopathy.
Hanna, BD; Lin, KY; Miller, K; O'Connor, MJ; Ravishankar, C; Rossano, JW; Shaddy, RE, 2018
)
2.64
"Disopyramide is a class Ia antiarrhythmic that historically was used for the treatment of arrhythmias; however, its contemporary use is often reserved for patients with HCM who are persistently symptomatic despite β-blockers or verapamil and have evidence of LVOT obstruction."( Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Coons, JC; Verlinden, NJ, 2015
)
2.58
"Disopyramide (Norpace) is a widely used, generally well tolerated antiarrhythmic agent. "( Hypoglycemic coma due to disopyramide toxicity.
Gillman, MW; Stapleton, JT, 1983
)
2.01
"Disopyramide (Norpace) is a recently released antiarrhythmic agent with quinidine-like actions, but structurally unique. "( Disopyramide (Norpace)-induced hypoglycemia.
Brown, LK; Goldberg, IJ; Rayfield, EJ, 1980
)
3.15
"Disopyramide is an effective class I antiarrhythmic drug and widely used for the treatment of arrhythmias, but it has anticholinergic side effects. "( Antiarrhythmic effects of optical isomers of disopyramide on canine ventricular arrhythmias.
Eto, K; Hashimoto, K; Nakamura, M; Xue, Y, 1996
)
2
"Disopyramide appears to be a safe and effective oral therapy in the prevention of potentially serious arrhythmias following myocardial infarction."( Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.
Besterman, EM; Jennings, G; Jones, MS; Kidner, PH; Model, DG; Turner, PP, 1976
)
1.49
"Disopyramide (D.) is a new antiarrhythmic agent, which is not related chemically to any of the known substances. "( [Antiarrhythmic treatment of ventricular ectropic arrhythmies with Disopyramide].
Guckenbiehl, H; Just, H; Lang, KF; Olbermann, M, 1976
)
1.93
"Disopyramide is a new antiarrhythmic drug with a pharmacological profile of action similar to that of quinidine and procainamide. "( Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978
)
3.14
"Disopyramide phosphate is a new antiarrhythmic drug that has been shown to possess significant antiarrhythmic effects in animals and man. "( Electrophysiological actions of disopyramide phosphate on canine ventricular muscle and purkinje fibers.
Kus, T; Sasyniuk, BI, 1975
)
1.98
"Disopyramide is a Vaughan-Williams class Ia antiarrhythmic, which is distinguished by its anticholinergic activity, which is due to its active metabolite: mono-N-alkyl disopyramide. "( [Effects of disopyramide on normal and pathological atrioventricular conduction].
Barnay, C, 1992
)
2.11
"Disopyramide is an antiarrhythmic drug similar to quinidine and used primarily to treat ventricular ectopic systoles. "( Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
Pappas, AA; Taylor, EH,
)
3.02
"Disopyramide is a group I antiarrhythmic drug which is mainly used for the treatment of ventricular and supraventricular rhythm disturbances. "( Disopyramide-induced hypoglycemia: case report and review of the literature.
Baumelou, A; Cacoub, P; Deray, G; Grimaldi, A; Jacobs, C; Soubrie, C, 1989
)
3.16
"S-Disopyramide is a drug of high hepatic extraction ratio in rabbits and R-disopyramide is of intermediate hepatic extraction ratio."( Stereoselective gastrointestinal clearance of disopyramide in rabbits treated with activated charcoal.
Huang, JD, 1988
)
1.09
"Disopyramide is a widely used class IA antiarrhythmic drug with a pharmacological profile of action similar to that of quinidine and procainamide. "( Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.
Brogden, RN; Todd, PA, 1987
)
3.16
"Disopyramide is an oral antiarrhythmic drug which reduces conduction velocity, prolongs duration of action potential and the effective refractory period, and exerts vagolytic properties. "( Fatal disopyramide intoxication from suicidal/accidental overdose.
Sathyavagiswaran, L, 1987
)
2.2
"Disopyramide is an antiarrhythmic agent with proven efficacy in the management of atrial and ventricular arrhythmias. "( Clinical pharmacokinetics of disopyramide.
Siddoway, LA; Woosley, RL,
)
1.87
"Disopyramide is an antiarrhythmic drug with concentration dependent protein binding within the therapeutic range. "( Total and free disopyramide by fluorescence polarization immunoassay and relationship between free fraction and alpha-1 acid glycoprotein.
Chen, BH; Pappas, AA; Taylor, EH, 1987
)
2.07
"Disopyramide is an antiarrhythmic drug that exhibits nonlinear binding to plasma proteins. "( Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay.
Meyer, MC; Raghow, G; Straughn, AB, 1985
)
2.03

Effects

Disopyramide has been successfully used to treat a variety of supraventricular and ventricular arrhythmias. It has the potential to suppress sinus node function and must be used cautiously in patients with the sick sinus syndrome.

ExcerptReferenceRelevance
"Disopyramide has a selective effect on potential reentry circuits in ischemic myocardium, and prolongs refractoriness in abnormal myocardium to a greater extent than its effect on the normal ventricle."( Actions of disopyramide on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs during the late post-myocardial infarction phase.
Brachmann, J; Cobbe, SM; Hoffmann, E; Kübler, W; Ritzenhoff, A; Senges, J, 1984
)
1.38
"Disopyramide has a selective effect on potential reentry circuits in ischemic myocardium, and prolongs refractoriness in abnormal myocardium to a greater extent than its effect on the normal ventricle."( Actions of disopyramide on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs during the late post-myocardial infarction phase.
Brachmann, J; Cobbe, SM; Hoffmann, E; Kübler, W; Ritzenhoff, A; Senges, J, 1984
)
1.38
"Disopyramide has the potential to suppress sinus node function and, therefore, must be used cautiously in patients with the sick sinus syndrome."( Disopyramide.
Desai, J; Morady, F; Scheinman, MM, 1982
)
2.43
"Disopyramide has been successfully used to treat a variety of supraventricular and ventricular arrhythmias. "( Electrophysiologic effects of disopyramide in children.
Kashani, IA; Shakibi, JG; Siassi, B, 1980
)
1.99
"Disopyramide has been shown not only to treat the bradycardia but also to control the hypotension."( Oral disopyramide in the treatment of recurrent neurocardiogenic syncope.
Bhaumick, SK; Mondal, BK; Morgan, S,
)
1.37
"Disopyramide has the advantage of being available both as an oral and an intravenous preparation and is a useful drug to be added to the list of more conventional anti-dysrhythmic agents."( Disopyramide--an effective treatment for lignocaine resistant ventricular dysrhythmias.
Green, AG, 1979
)
2.42
"Disopyramide, which has electrophysiologic properties similar to those of quinidine, probably caused the arrhythmia and should be added to the list of drugs associated with atypical ventricular tachycardia."( Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
Martin, RP; McMorrow, M; Meltzer, RS; Robert, EW, 1978
)
1.23
"Disopyramide has been shown in conditions of cholinergic blockade to have a depressant effect upon sinus node automaticity and the atrial refractoriness. "( Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods.
Birkhead, JS; Vaughan Williams, EM, 1977
)
2.05
"Disopyramide has nonlinear protein binding and thus the relationship between the extent of its bioavailability and AUC, the area under the plasma concentration-time curve, is nonlinear and absorption rate-dependent. "( The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
Upton, RA; Williams, RL, 1986
)
1.96

Actions

Disopyramide is useful in the management of patients with HCM. It does produce sodium channel blockade, but recovery from this effect is much slower than for quinidine or amitriptyline (time constant 12-50s)

ExcerptReferenceRelevance
"Thus disopyramide, probably because of its negative inotropic action, is useful in the management of patients with HCM when LV outflow obstruction is the main cause of the clinical-hemodynamic findings."( [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
Contini, GM; Dore, L; Franceschino, V; Ibba, GV; Terrosu, P, 1984
)
1.03
"Disopyramide does produce sodium channel blockade, but recovery from this effect is much slower than for quinidine or amitriptyline (time constant 12-50s)."( Differential effects of antiarrhythmic agents on post-pause repolarization in cardiac Purkinje fibres.
Bursill, JA; Campbell, TJ; Wyse, KR, 1996
)
1.02
"With disopyramide this increase was not significant."( Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
Caron, JF; Dupuis, BA; Kacet, S; Kher, AR; Lekieffre, JP; Libersa, CC; Poirier, JM; Wanszelbaum, H, 1985
)
1
"d-Disopyramide had a lower plasma clearance and renal clearance, a longer half-life, and a smaller apparent volume of distribution than 1-disopyramide."( In vivo interaction of the enantiomers of disopyramide in human subjects.
Blaschke, TF; Giacomini, KM; Nelson, WL; Pershe, RA; Turner-Tamiyasu, K; Valdivieso, L, 1986
)
1.09

Treatment

ExcerptReferenceRelevance
"Pretreatment with disopyramide had no effect on the hemodynamic response to adrenaline but caused a significant prolongation of Qtc duration before the adrenaline infusion."( Metabolic, hemodynamic, and electrocardiographic responses to increased circulating adrenaline: effects of pretreatment with class 1 antiarrhythmics.
Gullberg, B; Hansen, O; Johansson, BW, 1991
)
0.6

Toxicity

Disopyramide can have the serious side effect of hepatocellular toxicity. The risk of subsequent sudden cardiac death is low. Adenosine did not terminate tachycardia in any patient.

ExcerptReferenceRelevance
" Adenosine did not terminate tachycardia or have any serious adverse effect in any patient; both flecainide and disopyramide were significantly more effective than lignocaine, but flecainide had significantly more severe adverse effects than lignocaine."( Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE, 1990
)
0.49
" Excretion is reduced by impaired renal function, often found in the elderly, which may increase the toxic response."( Physiological factors affecting drug toxicity.
Bailey, K, 1983
)
0.27
" The dosage regimen of intravenous disopyramide evaluated was effective in 60% of patients with ventricular arrhythmia, induced no severe toxic effects, and rapidly achieved therapeutic serum levels that were maintained during continuous infusion."( Intravenous disopyramide: safety and efficacy of a new dosage regimen.
Beck, B; Benes, J; Reddy, CP, 1984
)
0.92
" The comparison of hemodynamic, electrocardiographic and toxic effects of mexiletine with those produced by other antiarrhythmics showed that mexiletine placed itself among the better tolerated antiarrhythmics during the administration of progressively increasing doses."( Hemodynamic, electrocardiographic and toxic effects of the intravenous administration of increasing doses of mexiletine in the dog. Comparison with similar effects produced by other antiarrhythmics.
Carlier, J, 1980
)
0.26
" This case report shows that disopyramide can have the serious side effect of hepatocellular toxicity and provides evidence of the association of hepatocellular damage and disseminated intravascular coagulation."( Disopyramide hepatotoxicity and disseminated intravascular coagulation.
Doody, PT, 1982
)
2
"We evaluated the electrophysiological mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline in seven patients, pilsicainide in two, and disopyramide in two, and procainamide in three) in the induction of orthodromic atrioventricular re-entrant tachycardia (AVRT)."( Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia.
Fujiki, A; Inoue, H; Tani, M; Yoshida, S, 1996
)
0.7
" The antiarrhythmics studied cause adverse reactions to the eye."( Interaction of quinidine, disopyramide and metoprolol with melanin in vitro in relation to drug-induced ocular toxicity.
Buszman, E; Rózańska, R, 2003
)
0.62
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Initiation of disopyramide in the outpatient setting is safe and the risk of subsequent sudden cardiac death is low."( Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.
Adler, A; Chan, RH; Fourey, D; Gollob, MH; Hindieh, W; Rakowski, H; Weissler-Snir, A, 2017
)
1.09
"Disopyramide is a safe and effective treatment for LVOTO-related symptoms in childhood obstructive HCM."( Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy.
Boleti, O; Cervi, E; Field, E; Kaski, JP; Norrish, G; Topriceanu, CC, 2023
)
3.8

Pharmacokinetics

Disopyramide phosphate (ritmilen) is an effective antiarrhythmic agent for atrial fibrillation paroxysms. The unbound clearance and half-life of S(+)-disopyramid averaged 604 ml/min and 3.5 g/min.

ExcerptReferenceRelevance
" Pharmacokinetic parameters of DP enantiomers based on total plasma concentrations were not significantly different."( Human pharmacokinetics and metabolism of disopyramide enantiomers.
Gibassier, D; Le Corre, P; Le Verge, R; Sado, P, 1991
)
0.55
"6 l h-1 and 89 vs 50 l, respectively), whereas no significant difference in half-life could be demonstrated."( Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine.
Angelo, HR; Bonde, J; Kampmann, JP; Nygaard, E; Pedersen, LE; Ramsing, T, 1991
)
0.56
" The pharmacokinetic parameters were calculated using a two-compartment model."( Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
Hatano, M; Inoue, M; Kuno, T; Maeda, H; Maejima, M; Nagura, Y; Okada, K; Takahashi, S; Yanai, M, 1991
)
0.55
" This study examines the detailed pharmacokinetic characteristics of DP and MND when given simultaneously or separately to dogs."( Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
Cook, CS; Gupta, S; Gwilt, PR; Karim, A; Kowalski, K; Oppermann, J,
)
0.45
" On the other hand, the elimination half-life of antiarrhythmic agents that have a large volume of distribution and are highly cleared by the liver may be twice as long in patients with CHF compared with normal subjects."( Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
Echt, DS; Roden, DM; Woosley, RL, 1986
)
0.27
" On the basis of the pharmacokinetic changes observed (and provided that plasma protein binding is unchanged), D oral dose should be reduced by 1/3, without modifying the dosage interval."( Disopyramide pharmacokinetics in the elderly after single oral administration.
Donatella, P; Gabriella, C; Raffaella, M; Roberto, P; Sergio, B; Vitaliano, B, 1988
)
1.72
" Orally administered activated charcoal significantly decreased the area under the serum concentration curve of R-disopyramide, whereas the same treatment had no effect on that of S-disopyramide."( Stereoselective gastrointestinal clearance of disopyramide in rabbits treated with activated charcoal.
Huang, JD, 1988
)
0.74
" Elimination half-life is approximately 7 hours in normal subjects and patients, but is prolonged in patients with renal insufficiency (creatinine clearance less than 60 ml/min)."( Clinical pharmacokinetics of disopyramide.
Siddoway, LA; Woosley, RL,
)
0.42
" Thus even with intravenous disopyramide therapy there are problems with changing pharmacokinetic parameters after myocardial infarction."( Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
Bryson, SM; Elliott, HL; Thomson, AH, 1986
)
2.01
" In the same subjects the sensitivity of PEP to minor negative inotropic effects of mexiletine and disopyramide measured at Cmax was confirmed."( Uncorrected pre-ejection period: a simple non-invasive measurement for pharmacodynamic screening of inotropic activity.
Boissel, JP; Galleyrand, J; Rousson, D; Silie, M, 1987
)
0.49
"Based on pharmacodynamic and pharmacokinetic studies in 42 patients with paroxysmal and extrasystolic abnormalities of the rhythm it was established that disopyramide phosphate (ritmilen) is an effective antiarrhythmic agent for atrial fibrillation paroxysms."( [Pharmacodynamics and pharmacokinetics of disopyramide phosphate].
Beloborodov, VL; Klimov, AV; Kuz'mina, MM; Ol'binskaia, LI; Tiukavkina, NA,
)
0.59
" On the basis of the intravenous tracer data, the volume of distribution, binding to plasma proteins, total plasma clearance, renal clearance and elimination half-life of disopyramide and mono-N-dealkyl disopyramide were the same in Studies I and II."( Disopyramide pharmacokinetics in patients with acute myocardial infarction.
Huikuri, H; Jounela, AJ; Pentikäinen, PJ; Wilen, G, 1985
)
1.91
"We studied the haemodynamic and pharmacokinetic effects of intravenous disopyramide phosphate in 12 patients (average age, 59 years) with proven transmural myocardial infarction, whose symptoms began less than 12 h prior to the study."( Intravenous disopyramide in acute myocardial infarction: a haemodynamic and pharmacokinetic study.
Cameron, J; Norris, R; Pritchard, D; Ravenscroft, P; Stafford, W,
)
0.74
" Unbound concentrations of disopyramide were modelled by an open one-compartment pharmacokinetic model with a zero-order absorption rate and a lag time."( Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.
Blume, CD; Holford, NH; Thibonnier, M; Upton, RA; Williams, RL, 1984
)
0.82
" This paper reviews the effect of this type of binding on both the pharmacokinetic and pharmacodynamic properties of the drug."( Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
Blaschke, TF; Giacomini, KM, 1984
)
0.48
" The therapeutic dose, clearance, extraction coefficient, bioavailability and half-life are the object of particular study."( [Pharmacokinetics of anti-arrhythmics. 2. Clinical applications].
Bricaud, H; Lévy, RH; Lévy, S, 1980
)
0.26
" With the exception of maximum concentration (C max), which was only slightly modified, and of the apparent distribution volume which remained unchanged, all the other pharmacokinetic blood parameters (t max, concentration at 24th hour, elimination constant (ke h-1), elimination half-life, area under the curve and plasma clearance) were significantly modified in the CRF group; in particular, the elimination half-life was significantly increased (for 22 cases of CRF with mean plasma creatinine greater than 250 microM at 16."( Pharmacokinetics of disopyramide in patients with chronic renal failure.
Francois, B; Lussignol, M; Mallein, R; Rondelet, J, 1983
)
0.59
" 3 Mean elimination half-life (6."( Disopyramide pharmacokinetics during recovery from myocardial infarction.
Bryson, SM; Cairns, CJ; Whiting, B, 1982
)
1.71
" Because of this property, controversy exists in the literature regarding the pharmacokinetic properties of the drug."( The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
Blaschke, TF; Giacomini, KM; Swezey, SE; Turner-Tamiyasu, K, 1982
)
0.49
" 2 OPT uses prior information on the distribution of population pharmacokinetic parameters and plasma drug concentration measurements to obtain the "most likely' set of parameters for the individual."( OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.
Bryson, SM; Kelman, AW; Whiting, B, 1982
)
0.26
" 2 Absorption half-life and volume of distribution were similar to those seen in normal subjects."( Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
Hamer, NA; Henry, JA; Johnston, A; Warrington, SJ, 1980
)
0.56
" In conclusion, it was shown that a pharmacodynamic interaction contributes to the electrocardiographic adverse reaction (i."( Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats.
Hanada, E; Iga, T; Kotaki, H; Ohtani, H; Sato, H; Sawada, Y, 1999
)
0.54
" The results of the PK-PD analysis indicated that the enhanced pharmacological response under miconazole co-administration was simply caused by a pharmacokinetic change."( Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
Iwanaga, K; Kakemi, M; Maekawa, C; Miyazaki, M; Morimoto, K, 2000
)
0.6
" Population pharmacokinetic parameters of DP racemate, enantiomers (S(+)-DP, R(-)-DP), and their unbound concentrations (uDP, S(+)-uDP and R(-)-uDP) were analyzed using the nonlinear mixed effect model (NONMEM) program."( Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
Aso, R; Katoh, T; Ogata, H; Ohashi, K, 2001
)
0.54
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
"To estimate the population pharmacokinetic parameters of disopyramide using non-linear mixed effects modelling."( Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients.
Kinoshita, H; Orio, K; Terao, K; Yukawa, E; Yukawa, M, 2005
)
0.83
"The final pharmacokinetic model was Cl (L/h)=3."( Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients.
Kinoshita, H; Orio, K; Terao, K; Yukawa, E; Yukawa, M, 2005
)
0.59
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Finally, this assay was successfully applied to pharmacokinetic analysis of disopyramide and mono-isopropyl-disopyramide after oral and intravenous administration of disopyramide."( A rapid and sensitive liquid chromatography/tandem mass spectrometry assay for simultaneous quantitation of disopyramide and its major metabolite, mono-isopropyl-disopyramide, in rat plasma and its application to a pharmacokinetic study.
Ahn, SH; Pham, QK; Seo, H, 2018
)
0.92

Compound-Compound Interactions

ExcerptReferenceRelevance
"The efficacy of mexiletine used alone, and in combination with a class Ia antiarrhythmic drug, was assessed in 159 previously drug-refractory patients with ventricular tachycardia (VT) during serial electrophysiologic studies and during long-term (5-year) clinical follow-up."( Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias.
Garan, H; McElroy, M; McGovern, B; Newell, JB; Ruskin, JN; Schoenfeld, MH; Whitford, EG, 1988
)
0.27
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

Plasma concentrations and bioavailability of disopyramide following repeated administration of standard capsules and controlled-release tablets have been compared. The study further characterized the impact of concentration-dependent protein binding on the bioavailability and clinical use of the immediate-release (IR) and controlled release (CR) dosage forms.

ExcerptReferenceRelevance
" Dissolution and plasma concentrations show no significant differences in bioavailability between the two polymorphs."( Polymorphism of disopyramide.
Freeman, M; Gunning, SR; Stead, JA, 1976
)
0.6
" DP was absorbed rapidly and its absolute oral bioavailability was about 70%."( Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
Campion, J; Karim, A; Kook, C; Novotney, RL; Zagarella, J,
)
0.38
" The peak plasma concentration of disopyramide in association with cisapride oral administration was significantly higher, and the apparent absorption rate constant and lag time of disopyramide were about 2-fold higher and 2-fold shorter, respectively, than for disopyramide alone."( Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide.
Akima, M; Azumi, T; Fukuzaki, H; Inatome, T; Kuroda, T; Nakamura, H; Takanashi, H; Yogo, K; Yoshihara, Y, 1992
)
0.79
" DP and MND were both relatively well absorbed and showed similar pharmacokinetic characteristics."( Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
Cook, CS; Gupta, S; Gwilt, PR; Karim, A; Kowalski, K; Oppermann, J,
)
0.45
" The drug is usually well absorbed orally."( Fatal disopyramide intoxication from suicidal/accidental overdose.
Sathyavagiswaran, L, 1987
)
0.75
" The drug is well absorbed and undergoes virtually no first-pass metabolism."( Clinical pharmacokinetics of disopyramide.
Siddoway, LA; Woosley, RL,
)
0.42
"Disopyramide has nonlinear protein binding and thus the relationship between the extent of its bioavailability and AUC, the area under the plasma concentration-time curve, is nonlinear and absorption rate-dependent."( The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
Upton, RA; Williams, RL, 1986
)
1.96
" Unbound concentrations of disopyramide were modelled by an open one-compartment pharmacokinetic model with a zero-order absorption rate and a lag time."( Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.
Blume, CD; Holford, NH; Thibonnier, M; Upton, RA; Williams, RL, 1984
)
0.82
"The pharmacokinetics and bioavailability of total (bound plus unbound) and unbound disopyramide were compared following the simultaneous administration of an oral dose of disopyramide and an intravenous dose of 14C-disopyramide in five normal volunteers and in 11 patients with congestive heart failure."( Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
Haughey, DB; Leier, CV; Lima, JJ, 1984
)
1.94
" The therapeutic dose, clearance, extraction coefficient, bioavailability and half-life are the object of particular study."( [Pharmacokinetics of anti-arrhythmics. 2. Clinical applications].
Bricaud, H; Lévy, RH; Lévy, S, 1980
)
0.26
" The bioavailability of disopyramide was the same after capsules and CR tablets."( Plasma concentration of disopyramide given as capsules and controlled release tablets.
Arnman, K; Graffner, C; Rikner, L; Ryden, L; Voog, L, 1983
)
0.88
" Comparison of the plasma concentrations in a subsequent cross-over study with disopyramide plain capsules 150 mg every 6 h and SR tablets 250 mg every 12 h, each being administered for 3 days to attain a steady state, showed that the bioavailability and the variation of the plasma concentration were similar with both regimens."( Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
Bakke, OM; Lien, E, 1983
)
0.83
"1 Previous pharmacokinetics studies of disopyramide in patients with ischaemic heart disease include unexplained reports of poor bioavailability and extremely long elimination half-lives which undermine accepted dosage recommendations."( Disopyramide pharmacokinetics during recovery from myocardial infarction.
Bryson, SM; Cairns, CJ; Whiting, B, 1982
)
1.98
" and AUC oral) showed that DP was almost completely absorbed, its bioavailability being 97."( Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
Amlie, JP; Bredesen, JE; Landmark, K; Simonsen, S; Thaulow, E, 1981
)
0.59
"Plasma concentrations and bioavailability of disopyramide following repeated administration of standard capsules and controlled-release tablets have been compared."( Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
Forssell, G; Graffner, C; Nordlander, R; Nyquist, O, 1980
)
0.81
"The stable isotope co-administration technique for estimating the bioavailability of drugs has been investigated in a series of experiments using rhesus monkeys."( The absorption of disopyramide in animals determined using a stable isotope co-administration technique.
Ford, GC; Forrest, TJ; Haskins, NJ; Palmer, RF; Spalton, PN; Waddell, KA; Walls, CM, 1980
)
0.59
"This study further characterized the impact of concentration-dependent protein binding on the bioavailability and clinical use of the immediate-release (IR) and controlled-release (CR) dosage forms of disopyramide after single doses and during steady-state conditions in ten healthy volunteers."( Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms.
Bauman, JL; Fischer, JH; Hoon, TJ; Piscitelli, DA; Schoen, MD, 1994
)
0.75
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The relationship between the serum concentration and the pharmacological effect of disopyramide was investigated quantitatively to estimate the extent of its oral bioavailability (EBA(p."( Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
Iwanaga, K; Kakemi, M; Maekawa, C; Miyazaki, M; Morimoto, K, 2000
)
0.82
"363, where Cl is total body clearance, Vd is apparent volume of distribution, k(a) is absorption rate constant, TBW is total bodyweight (kg), AGE is age (years), Conc is the concentration of disopyramide (microg/mL), and DOSE>or=5=1 for patient received 5 mg/kg/day of disopyramide dosage or over and 0 otherwise."( Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients.
Kinoshita, H; Orio, K; Terao, K; Yukawa, E; Yukawa, M, 2005
)
0.78
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Antiarrhythmic agents (quinidine, disopyramide, prajmaliumbitartrate, propafenone) exert a negative inotropic effect on left ventricular function as far as it can be judged from the measurement of STI. Disopyramid caused a parallel shift of the dose-response curves for acetylcholine, McN-A-343, and carbachol to the right in guinea pig taenia caeci.

ExcerptRelevanceReference
" The dosage of disopyramide phosphate should be sufficiently high and must be individualized."( [Clinical studies of the antiarrhythmic efficacy of disopyramide phosphate (Norpace) (author's transl)].
Smith, WS, 1978
)
0.86
" The dosage should be adapted with respect to the patient's weight and renal function."( [Antiarrhythmic action of disopyramide: a study of plasma levels].
Besse, P; Page, A; Pic, A, 1979
)
0.56
" Disopyramide is largely excreted unchanged and dosage should be reduced in patients with impaired renal function, in accordance with creatinine clearance values."( Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978
)
2.61
" The basic principles of pharmacokinetics are outlined and their application to the design of dosage regimens described."( Pharmacokinetics of antiarrhythmic drugs.
Shand, DG; Woosley, RL, 1978
)
0.26
" The results clearly indicate that at the dosage used, the four antiarrhythmic agents (quinidine, disopyramide, prajmaliumbitartrate, propafenone) exert a negative inotropic effect on left ventricular function as far as it can be judged from the measurement of STI."( [The effect of some antiarrhythmic drugs on systolic time intervals in normal subjects (author's transl)].
Breithardt, G; Jochum, E; Kuhn, H; Seipel, L, 1978
)
0.48
" It is important to know how the pharmacokinetics of a drug vary with different disease states so that appropriate adjustments to dosage can be made."( Series on pharmacology in practice. 2. Antiarrhythmic drug therapy.
Federman, J; Vlietstra, RE, 1979
)
0.26
"The antiarrhythmic agent disopyramide, in a dosage of 200 mg/8 h, was given to 7 cardiac patients."( Disopyramide plasma levels in cardiac patients on maintenance therapy.
Landmark, K; Larsen, A; Storstein, L, 1979
)
2.01
" It is concluded that at therapeutic dosage disopyramide does not present deleterious hemodynamic effects in animals and proves to be a valid alternative to other traditional antiarrhythmic agents."( [Hemodynamic effects of disopyramide and procainamide in open-chest animals].
Binetti, G; Branzi, A; Magelli, C; Magnani, B; Malini, PL; Specchia, S; Zannoli, R, 1978
)
0.83
" Intravenous therapy with disopyramide in the dosage regimen employed appears to be moderately effective against supraventricular arrhythmia and particularly effective against ventricular arrhythmia with minimal toxicity."( The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
Deano, DA; Ehsani, AI; Mautner, RK; Rosen, KM; Sherman, RH; Wu, D, 1977
)
0.8
" During dosing (10 mg kg-1 twice a day for 10 days) no effects on the electrocardiogram, monitored in conscious animals, were observed despite modest reductions (15-18%) in the maximum rate of depolarization of papillary muscle excised 1 or 6 h after completion of the dosing regime."( Antiarrhythmic, electrophysiological and haemodynamic effects of prolonged oral dosing with Org 7797 in the anaesthetized rat.
Delbressine, L; Harris, N; Kane, KA; Muir, AW; Winslow, E, 1992
)
0.28
" This complexity seems to be the most important reason for the limited reliability of serum concentration measurements for predicting the best dosage for the individual patient."( [Torsades de pointes ventricular tachycardia induced by disopyramide at therapeutic serum concentration].
Aarskog, D; Reikvam, A, 1992
)
0.53
" A sustained-release preparation of DP may be required for pediatric patients to minimize a large fluctuation of plasma drug levels during the dosing intervals."( Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias.
Chiba, K; Echizen, H; Ishizaki, T; Ishizawa, A; Koike, K; Nakamoto, M, 1992
)
0.52
" In five out of those patients, we attempted combined therapy with a reduced dosage of those drugs that caused side effects."( Efficacy of disopyramide and mexiletine used alone or in combination in the treatment of ventricular premature beats.
Hiraoka, M; Motomiya, T; Sakurada, H, 1991
)
0.66
" These findings indicate that patient AAG levels can provide valuable information permitting the rapid estimation of unbound DP concentrations, the pharmacologically active fraction, and the development of effective DP dosage regimens."( A simple method for the simulation of unbound serum disopyramide concentration in patients.
Iseki, K; Kishino, S; Kohri, N; Miyazaki, K; Nomura, A; Yasuda, H, 1991
)
0.53
"Antiarrhythmic therapy was chosen for 3-7 days by modified chronic electrophysiological study at three stages: (1) the efficacy of a drug, its action onset and termination were defined; (2) a dosage was chosen on an individual basis and the duration of drug potency was specified; (3) the dosage regimen of a drug given as a course therapy was confirmed by the results of trials."( [Evaluation of the possibility of selection of individual anti-arrhythmia therapy].
Antonchenko, IV; Borisova, EV; Chekhov, AM; Gimrikh, EO; Plekhanov, IG; Popov, SV; Savenkova, GM, 1991
)
0.28
" Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level."( Antiarrhythmic drug therapy. Recent advances and current status.
Somberg, J, 1985
)
0.27
" Propafenone controlled dysrhythmia very well in 4 out of the ten patients, and satisfactorily in another one at a dosage ranging from 450 to 900 mg/day in 3 or 4 divided doses; this result was documented using continuous 24 hr."( [Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents].
Amiel, A; Boutaud, P; Ciber, M; Demange, J; Guillem, JP; Herpin, D; Maarek-Charbit, M, 1989
)
0.28
" Studies have demonstrated that effective blood levels are obtained with the 12-hour dosing schedule for controlled-release disopyramide phosphate in both normal volunteers and in patients with cardiac arrhythmias."( Long-term use of controlled-release disopyramide in patients with severe ventricular arrhythmias.
Paulk, EA, 1987
)
0.75
" On the basis of the pharmacokinetic changes observed (and provided that plasma protein binding is unchanged), D oral dose should be reduced by 1/3, without modifying the dosage interval."( Disopyramide pharmacokinetics in the elderly after single oral administration.
Donatella, P; Gabriella, C; Raffaella, M; Roberto, P; Sergio, B; Vitaliano, B, 1988
)
1.72
" The principal use of the drug is to suppress ventricular extrasystoles with usual oral dosage of 100 to 200 mg every 6 h, until blood levels of 2 to 4 micrograms/mL are attained."( Fatal disopyramide intoxication from suicidal/accidental overdose.
Sathyavagiswaran, L, 1987
)
0.75
" Changes in protein binding do not, however, alter free disopyramide or metabolite concentrations, both of which are dependent only on dosage and intrinsic clearance."( Clinical pharmacokinetics of disopyramide.
Siddoway, LA; Woosley, RL,
)
0.67
" With the dosage regimen used serum concentrations considerably above the suggested therapeutic level were achieved in the majority of patients."( Displacement of lidocaine from human plasma proteins by disopyramide.
Angelo, HR; Bonde, J; Burgaard, P; Graudal, N; Jensen, NM; Kampmann, JP; Pedersen, LE, 1987
)
0.52
" 5 The results suggest that a total concentration of disopyramide within the therapeutic range may not be a reliable guide for a safe dosing scheme in patients with severe nephrotic syndrome, particularly during the exacerbation period."( Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.
Echizen, H; Ishizaki, T; Saima, S, 1987
)
1.97
" The clinical implication of the present findings appear to be that the dosage of disopyramide should be reduced by 25% when it is given intravenously to patients with decreased hepatic function."( Kinetics of disopyramide in decreased hepatic function.
Angelo, HR; Balsløv, S; Bonde, J; Graudal, NA; Kampmann, JP; Pedersen, LE; Svendsen, TL, 1986
)
0.88
" This could be attributed to a relatively low dosage and slow infusion speed."( Effects of four antiarrhythmic drugs on the induction and termination of paroxysmal supraventricular tachycardia.
Ishinaga, T; Komatsu, C; Tateishi, O; Tokuhisa, Y; Yoshimura, S, 1986
)
0.27
" The elimination half-life ranges from 12-27 hours in patients with normal renal function, allowing convenient dosing regimens of 100-200 mg twice daily in most patients."( Flecainide: a new prototype antiarrhythmic agent.
Anderson, JL; Nappi, JM,
)
0.13
" The suggested dosage regimen of disopyramide seems to result in a satisfactory response."( Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Svendsen, TL, 1985
)
0.93
" The results indicate that it might be advisable to reduce the dosage of disopyramide by approximately 30% in elderly non-smokers compared with young subjects."( The influence of age and smoking on the elimination of disopyramide.
Angelo, HR; Bonde, J; Bødtker, S; Kampmann, JP; Pedersen, LE; Svendsen, TL, 1985
)
0.75
" Special consideration, however, must be given with regard to drug selection and dosage in order to avoid adverse effects on the mother and fetus."( Antiarrhythmic drug therapy during pregnancy.
Elkayam, U; Frishman, W; Rotmensch, HH, 1983
)
0.27
" If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate."( New directions in antiarrhythmic drug therapy.
Somberg, JC, 1984
)
0.27
" Disopyramide at high concentrations potentiated the contractile response of mesenteric arteries to norepinephrine and tyramine, while, in contrast, procainamide and quinidine shifted the dose-response curve for norepinephrine to the right."( Influence of disopyramide, compared with procainamide and quinidine, on isolated dog arteries in response to transmural stimulation and norepinephrine.
Konishi, M; Miyazaki, M; Okunishi, H; Toda, N,
)
1.41
" During this time, clinical experience has refined our knowledge of this agent, allowing revision of dosing guidelines and better selection of patients."( Disopyramide: six years' experience.
Wallace, AG; Wilson, RR, 1983
)
1.71
" Although both drugs significantly reduced VPDs relative to placebo, ethmozine was a superior antiarrhythmic drug in ach9eving near-total abolition of VPDs (30% of patients), which was never observed during disopyramide dosing (p less than ."( Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design.
English, L; Francis, MJ; Kopelen, H; Mann, DE; Norton, HJ; Pratt, CM; Quinones, MA; Roberts, R; Taylor, AA; Young, JB, 1984
)
0.77
"Measurement of drug levels is becoming increasingly popular to optimise the dosage of various drugs."( Reliability of antiarrhythmic drug plasma concentration monitoring.
Follath, F; Ganzinger, U; Schuetz, E,
)
0.13
" In a clinical study, nine healthy male volunteers were dosed with disopyramide to steady-state concentration."( Hypoglycemia in patients receiving disopyramide phosphate.
Cohen, A; Nitzberg, DM; Schubert, EN; Strathman, I, 1983
)
0.78
" Medication dosages, dosing intervals, and time elapsed from last dosage until blood sampling were determined."( Long-term antiarrhythmic therapy. Problem of low drug levels and patient noncompliance.
Fuster, V; Goldman, ME; Kupersmith, J; Schweitzer, P; Squire, A; Stern, EH, 1984
)
0.27
" The latter, however, was taking antiarrhythmic drugs at a dosage less than that proved to be effective during electropharmacological testing."( [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation].
Delise, P; Di Pede, F; Piccolo, E; Raviele, A, 1984
)
0.27
" For a drug with capacity-limited, binding-sensitive elimination like disopyramide, concentration-dependent binding to plasma proteins produces a non-linear relationship between dosing rate and total plasma concentrations of the drug."( Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
Blaschke, TF; Giacomini, KM, 1984
)
0.71
" This may also explain their poor dose-response relationships and great interindividual variability in plasma concentration data."( Potential applications of free drug level monitoring in cardiovascular therapy.
Cerskus, I; Roden, DM; Siddoway, LA; Thompson, K; Woosley, RL, 1984
)
0.27
" The patients received the appropriate dosage for 7 or more days before repeat radionuclide angiography was performed."( Effects on ventricular function of disopyramide, procainamide and quinidine as determined by radionuclide angiography.
Gebhardt, VA; Goddard, MD; Gryfe-Becker, B; Nichol, PM; Prato, FS; Rechnitzer, PA; Wisenberg, G; Zawadowski, AG, 1984
)
0.54
"The efficacy and safety of a new dosage regimen of intravenous disopyramide in ventricular arrhythmias were evaluated in 10 patients."( Intravenous disopyramide: safety and efficacy of a new dosage regimen.
Beck, B; Benes, J; Reddy, CP, 1984
)
0.89
" Searle), literature demonstrating its efficacy in maintaining uniform serum drug levels over a 12-h dosing interval is derived from only normal healthy volunteers."( Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
Zema, MJ, 1984
)
0.48
" After treatment either with capsules or CR tablets, plasma concentrations of disopyramide and its metabolite N-deisopropyldisopyramide were similar within 1 dosage interval."( Plasma concentration of disopyramide given as capsules and controlled release tablets.
Arnman, K; Graffner, C; Rikner, L; Ryden, L; Voog, L, 1983
)
0.8
" The results suggest that the dosage of disopyramide should be decreased when plasma creatinine values are greater than 250 microM, and creatinine clearance is less than 30 ml/min."( Pharmacokinetics of disopyramide in patients with chronic renal failure.
Francois, B; Lussignol, M; Mallein, R; Rondelet, J, 1983
)
0.86
" Dosage regimen must therefore be based on individual response and controlled by the clinical effect and estimates of disopyramide serum concentration."( Disopyramide kinetics in renal impairment: determinants of interindividual variability.
Burk, M; Peters, U, 1983
)
1.92
" The high incidence of side-effects was probably due to the high dosage used."( Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias.
Van Durme, JP, 1980
)
0.26
"1 Previous pharmacokinetics studies of disopyramide in patients with ischaemic heart disease include unexplained reports of poor bioavailability and extremely long elimination half-lives which undermine accepted dosage recommendations."( Disopyramide pharmacokinetics during recovery from myocardial infarction.
Bryson, SM; Cairns, CJ; Whiting, B, 1982
)
1.98
"The serum concentration/time profiles resulting from two oral disopyramide dosage regimes were studied in ten patients with ischaemic heart disease."( Oral disopyramide dosage regimes in ischaemic heart disease.
Bryson, SM; Fotheringham, GH; Struthers, MG; Whiting, B, 1982
)
1.02
" 3 Complex dosage regimes and non-steady state conditions can be handled."( OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.
Bryson, SM; Kelman, AW; Whiting, B, 1982
)
0.26
" Thus, the dosage of oral disopyramide obviously needs to be increased in these patients to achieve therapeutic concentrations in the acute phase."( The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
Jounela, AJ; Oksanen, K; Pentikäinen, PJ, 1982
)
0.87
" It is suggested that adjustment of dosage is advisable in patients with renal dysfunction or left heart failure."( Study of an anti-arrhythmic agent, disopyramide, in delayed action form ('Ritmoforine' Retard).
Nauta, IL; van de Calseyde, JF, 1981
)
0.54
" Thus, Disopyramide given intravenously and orally in therapeutic dosage is a potent myocardial depressant in man."( [The effect of disopyramide of left ventricular function: an echocardiographic study of the extent and time course (author's transl)].
Angermann, C; Autenrieth, G, 1981
)
1.07
" The animals were dosed orally with a solution containing both disopyramide phosphate (5 mg kg-1) and [13C, 15N]disopyramide phosphate (5 mg kg-1)."( The absorption of disopyramide in animals determined using a stable isotope co-administration technique.
Ford, GC; Forrest, TJ; Haskins, NJ; Palmer, RF; Spalton, PN; Waddell, KA; Walls, CM, 1980
)
0.83
" Hence, dosage modification for disopyramide is necessary only when renal function is severely impaired."( Disposition kinetics of disopyramide in patients with renal insufficiency.
Azarnoff, DL; Cunningham, JL; Shen, DD; Shudo, I,
)
0.72
"This study further characterized the impact of concentration-dependent protein binding on the bioavailability and clinical use of the immediate-release (IR) and controlled-release (CR) dosage forms of disopyramide after single doses and during steady-state conditions in ten healthy volunteers."( Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms.
Bauman, JL; Fischer, JH; Hoon, TJ; Piscitelli, DA; Schoen, MD, 1994
)
0.75
" Fluctuations in ECG intervals during usual dosing were observed only with IR disopyramide."( Immediate- versus controlled-release disopyramide: importance of saturable binding.
Barbey, JT; Davies, RF; Roden, DM; Shaw, L; Siddoway, LA; Woosley, RL, 1993
)
0.79
"Because of saturable plasma binding, total plasma concentrations underestimate fluctuations in unbound disopyramide during usual dosing and are insensitive to significant differences between IR and CR formulations."( Immediate- versus controlled-release disopyramide: importance of saturable binding.
Barbey, JT; Davies, RF; Roden, DM; Shaw, L; Siddoway, LA; Woosley, RL, 1993
)
0.77
" Although coadministration of EM with DP gave enhanced QT prolongation compared to dosing with DP alone, EM did not affect the pharmacokinetics of DP."( Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats.
Hanada, E; Iga, T; Kotaki, H; Ohtani, H; Sato, H; Sawada, Y, 1999
)
0.54
" For this purpose, we plotted a dose-response curve for adrenaline by calculating the arrhythmic ratio, which is the number of ventricular ectopic beats induced by adrenaline divided by the total heart rate, and observed the changes in the arrhythmic ratio-adrenaline dose relation before and after administration of class I drugs."( QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide.
Aye, NN; Hashimoto, K; Miyamoto, S; Teramatsu, T; Zhu, B, 2000
)
0.6
" The model predicted doses were identical to the actual doses, regardless of the dosing rates."( Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
Iwanaga, K; Kakemi, M; Maekawa, C; Miyazaki, M; Morimoto, K, 2000
)
0.6
"363, where Cl is total body clearance, Vd is apparent volume of distribution, k(a) is absorption rate constant, TBW is total bodyweight (kg), AGE is age (years), Conc is the concentration of disopyramide (microg/mL), and DOSE>or=5=1 for patient received 5 mg/kg/day of disopyramide dosage or over and 0 otherwise."( Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients.
Kinoshita, H; Orio, K; Terao, K; Yukawa, E; Yukawa, M, 2005
)
0.78
"Application of the findings in this study to patient care may permit selection of an appropriate initial maintenance dosage to achieve target disopyramide concentrations and the desired therapeutic effect."( Population pharmacokinetic investigation of disopyramide by mixed effect modelling using routine clinical pharmacokinetic data in Japanese patients.
Kinoshita, H; Orio, K; Terao, K; Yukawa, E; Yukawa, M, 2005
)
0.79
" Appropriate dosing and monitoring of disopyramide are important to mitigate the potential for anticholinergic adverse events and proarrhythmias."( Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
Coons, JC; Verlinden, NJ, 2015
)
2.13
" This combination allows adequate dosing of disopyramide to achieve therapeutic goals."( Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.
Sherrid, MV, 2016
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Disopyramide Action Pathway478

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
regulator of G-protein signaling 4Homo sapiens (human)Potency2.11720.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency21.87610.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.11220.28189.721235.4813AID2326
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.68060.000229.305416,493.5996AID743075
arylsulfatase AHomo sapiens (human)Potency0.19011.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.47430.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency26.83250.143427.612159.8106AID1159516
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.56230.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency13.459123.934123.934123.9341AID1967
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency3.16230.010039.53711,122.0200AID1479
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency6.47760.01789.637444.6684AID588834
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency24.65360.425612.059128.1838AID504536
gemininHomo sapiens (human)Potency3.30660.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency5.97280.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency8.91250.009610.525035.4813AID1479145
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.84920.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)2.90000.40003.10009.7000AID692192
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)90.85000.21005.553710.0000AID386625; AID692194
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)1,036.70000.00032.63119.0000AID1207737
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)81.70002.03005.53139.9000AID386625
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)1,036.70000.00032.59559.0000AID1207737
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)75.36090.00091.901410.0000AID161281; AID240820; AID243151; AID408340; AID576612
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)1,036.70000.00032.63119.0000AID1207737
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)1,036.70000.00032.25459.6000AID1207737
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki62.00000.13002.37856.9000AID681375
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)100.00000.16003.95718.6000AID692196
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)66.00000.01002.765610.0000AID692195
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Ki30.00000.39002.32959.4000AID681368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (68)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (258)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID692188Therapeutic index, ratio of Cmax in human to IC50 for human OCT22011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID60244Antiarrhythmic effect in coronary artery ligated dog model at a dose of 5 mg/kg, administered intravenously and value noted at 1 hr1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of cis-2,6-dimethyl-alpha,alpha-diaryl-1-piperidinebutanols.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1764401Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID57154Antiarrhythmic potential in conscious dogs; the value ranges from +30 to +601983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis and antiarrhythmic activity of new [(dialkylamino)alkyl]pyridylacetamides.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID60854Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 5 mg/kg iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID76705Parasympatholytic activity and the % inhibition of guinea pig ileum contractile force at 4 mg/L of base was reported.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 3. Modifications to the linkage region (region 3).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID692185Cmax in human2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1764400Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1130758Antiarrhythmic activity in ip dosed CF1 mouse assessed as protection against chloroform-induced ventricular fibrillation1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiarrhythmic activity of some N-alkylbispidinebenzamides.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID62986Effect on ischemic arrhythmias was studied in dogs, by glass bead method. 60 mg/kg was administered perorally and percent sinus beats after compound administration, was reported.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID692186Therapeutic index, ratio of Cmax in human to IC50 for human OCT12011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID1764399Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1130759Acute toxicity in ip dosed CF1 mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiarrhythmic activity of some N-alkylbispidinebenzamides.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID57672Compound was evaluated for the activity rating1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of cis-2,6-dimethyl-alpha,alpha-diaryl-1-piperidinebutanols.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1764402Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID58564Compound was evaluated for maximum reduction of ectopic beats after oral administration at a dose 15 mg/kg to dog; IA means inactive1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID692193Inhibition of human OCT2 A270S mutant expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID58748Compound was evaluated for maximum reduction of ectopic beats after oral administration at a dose 25 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID60635Myocardial depression determined by monitoring the maximum rate of rise of left ventricular pressure in dog at 10 mg/kg dose1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: monobasic derivatives of disobutamide.
AID161144Percentage inhibition of specific binding of [3H]dofetilide (UK-68,798) from cardiac myocytes with blockade of delayed rectifier K+ channel1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID58778Duration of ischemic arrhythmias in dogs determined in minutes.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID692195Inhibition of human MATE1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID56512Activity duration index was evaluated in mixed-breed or Beagle dogs after intravenous administration.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID1148094Therapeutic index, ratio of LD50 for CF1 mouse to ED50 for antiarrhythmic activity in CF1 mouse1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Analogues of sparteine. 5. Antiarrhythmic activity of selected N,N'-disubstituted bispidines.
AID127207Compound was evaluated for ventricular tachycardia activity in intravenously administered mice, 3 min before aconitine infusion, at a dose of 10 mg/kg; S=significant antiarrhythmic effect1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID48138Effective refractory period (ERP) after iv administration to anesthetized, acutely infarcted cats at x mg/kg1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID205279Percentage inhibition of specific binding of [3H]batrachotoxin [3H]BTX) in sodium channel from cardiac myocytes at 10 uM1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID59526Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose 5 mg/kg iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID141948Inhibitory effect on muscarinic acetylcholine receptor binding affinity at a concentration of (10e -6)M1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID1130760Ratio of LD50 for CF1 mouse to ED50 for antiarrhythmic activity in CF1 mouse1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiarrhythmic activity of some N-alkylbispidinebenzamides.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60849Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of final sinus complexes after dose 25 mg/kg po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID692183Protein binding in human plasma2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID74038Effective dose in vivo for cardiac refractoriness (ERP) using paced guinea pig model1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID134406Lethal dose in mice (LD50) (following i.v. dosing)1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID75522Maximal follow rate showing the contractile frequencies of atria to electrical stimulation 10 min after incubation with right atria of guinea pig.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID127964Dose (po) required to double the prodrug pupil size1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID79351Antimuscarinic activity in guinea pig ileum1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: 4,4-disubstituted hexahydro-3H-pyrido[1,2-c]pyrimidin-3-ones and related compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID692192Inhibition of human OCT2 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID58775Duration for the antiarrhythmic activity was measured1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID62989Effect on ischemic arrhythmias was studied in dogs. 10 mg/kg was injected intravenously and percent sinus beats before compound administration, was reported.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1207737Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID112265Antiarrhythmic activity in chloroform induced ventricular arrhythmia in mice, 15 min before exposure to chloroform intraperitoneal administration1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Synthesis and biological action of the aminotetrahydroisoquinocarbazoles and related compounds: a new class of compounds with antiarrhythmic activity.
AID79338Anticholinergic activity is assessed in guinea pig ileum at 3 uM1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides.
AID79032Inhibitory concentration of guinea pig ileum longitudinal muscle strips to antagonize electrically stimulated contractions1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide.
AID59401Minimum effective dose evaluated in mixed-breed or Beagle dogs after intravenous administration1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID41709Hemodynamic effect of 5 mg/kg of compound was assessed in Beagle dogs by decrease in mean arterial pressure; max dose administered was 29 mg/kg1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: 4,4-disubstituted hexahydro-3H-pyrido[1,2-c]pyrimidin-3-ones and related compounds.
AID59517Activity against harris coronary ligation induced ventricular arrhythmia was measured as percent of initial sinus complexes after dose 25 mg/kg po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID62549No. of cases tested was measured on ouabain induced ventricular arrhythmia at 5 mg/kg, iv in dogs; 6/61990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID692189Therapeutic index, ratio of Cmax in human to IC50 for human OCT2 A270S mutant2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID151312Antiarrhythmic activity estimated by using the ouabain intoxicated dog model and the active dose of base in ouabain dog was reported.1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 3. Modifications to the linkage region (region 3).
AID58609Evaluated for ouabain-induced arrhythmia in anesthetized adult male mongrel dogs. Administered intravenously.1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides.
AID78122In vivo index of cardiac contractility using paced guinea pig model1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID692196Inhibition of human MATE2-K expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID692187Therapeutic index, ratio of Cmax in human to IC50 for human MATE12011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID232386Ratio of ED100 (Dose po required to double the prodrug pupil size in mice) to that of ED50 (50% inhibition of chloroform induced ventricular arrhythmia in mice)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID77947Minimal effective dose that resulted in significant delay in the onset of arrhythmias in guinea pig with iv administration of aconitine hydrochloride1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID134765Toxicity estimated in mouse as LD50 by intravenous administration1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID62988Effect on ischemic arrhythmias was studied in dogs. 10 mg/kg was injected intravenously and percent sinus beats after compound administration, was reported.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID76706Parasympatholytic activity was assessed from the ability to inhibit electrically stimulated contraction of isolated guinea pig ileum at 4 mg/L of base1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1764398Substrate activity at P-gp (unknown origin) assessed as net efflux ratio2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID681368TP_TRANSPORTER: inhibition of TEA uptake in OCT2-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID1148092Antiarrhythmic activity in ip dosed CF1 mouse by chloroform-fibrillation assay based ECG analysis1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Analogues of sparteine. 5. Antiarrhythmic activity of selected N,N'-disubstituted bispidines.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID127068Compound was evaluated for ventricular extrasystole activity, 3 min before aconitine infusion, at a dose of 10 mg/kg, intravenously administered in mice; S=significant antiarrhythmic effect1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID681375TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID141947Inhibitory effect on muscarinic acetylcholine receptor binding affinity at a concentration of (10e -5)M1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID1148093Acute toxicity in ip dosed CF1 mouse1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Analogues of sparteine. 5. Antiarrhythmic activity of selected N,N'-disubstituted bispidines.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID62987Effect on ischemic arrhythmias was studied in dogs, by glass bead method. 60 mg/kg was administered perorally and percent sinus beats before compound administration, was reported.1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID49079Ventricular fribrillation threshold (VFT) after iv administration to anesthetized, acutely infarcted cats at 5 mg/kg1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID59391Mean effective dose required to suppress ventricular ectopic rate in dog greater than or equal to 25% for a minimum duration of 10 min1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: monobasic derivatives of disobutamide.
AID61886Activity against ouabain-induced ventricular arrhythmia was measured as percent of sinus rhythm recovery at dose of 5 mg/kg iv1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID41714Antiarrhythmic activity in Beagle dogs following i.v. administration; minimum effective dose to suppress ventricular ectopic rate >/=25% for a minimum duration of 10 min.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: 4,4-disubstituted hexahydro-3H-pyrido[1,2-c]pyrimidin-3-ones and related compounds.
AID681944TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Disopyramide: 100 uM) in OCT1-expressing HeLa cells1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
AID1130763Ratio of ED25 for reduction in force of left atrial contraction in New Zealand rabbit to ED25 for reduction in maximum following frequency in New Zealand rabbit left atrium1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiarrhythmic activity of some N-alkylbispidinebenzamides.
AID57000Antiarrhythmic activity was evaluated in mixed-breed or Beagle dogs after intravenous administration.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID384956Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID60406Compound was evaluated for onset of action after oral administration at a dose 25 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID41707Decrease in myocardial contractility was determined by monitoring the maximum rate of rise of ventricular pressure in 10 Beagle dogs at a dose of 10 mg/kg1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: 4,4-disubstituted hexahydro-3H-pyrido[1,2-c]pyrimidin-3-ones and related compounds.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID41715The mean effective dose to suppress ventricular ectopic rate >=25% for a minimum duration of 10 minutes was reported.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: 4,4-disubstituted hexahydro-3H-pyrido[1,2-c]pyrimidin-3-ones and related compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID60246Antiarrhythmic effect in coronary artery ligated dogs model at a dose of 5 mg/kg, value noted at end dose.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of cis-2,6-dimethyl-alpha,alpha-diaryl-1-piperidinebutanols.
AID692184Therapeutic index, ratio of Cmax in human to IC50 for human MATE2-K2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID58769Compound was evaluated for duration of action after oral administration at a dose 25 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID588988Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OCT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID127210Compound was evaluated for ventricular tachycardia activity in perorally administered mice, 30 min before aconitine infusion, at a dose of 30 mg/kg; S=significant antiarrhythmic effect1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID58776Duration for the sinus rhythm recovery was measured1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antiarrhythmic activity of new benzofuran derivatives.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID79373Mean dissociation constant was measured for acetylcholine-induced contractions1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide.
AID60245Antiarrhythmic effect in coronary artery ligated dogs model at a dose of 5 mg/kg, administered intravenously and value noted at 20 min1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of cis-2,6-dimethyl-alpha,alpha-diaryl-1-piperidinebutanols.
AID1130762Toxicity in New Zealand rabbit assessed as reduction in force of left atrial contraction1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiarrhythmic activity of some N-alkylbispidinebenzamides.
AID127205Compound was evaluated for ventricular extrasystole, 30 min before aconitine infusion, at a dose of 30 mg/kg, perorally administered in mice; S=significant antiarrhythmic effect1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antiarrhythmic activity of new 1-[1-[2-[3-(alkylamino)-2-hydroxypropoxy]phenyl]vinyl]-1 H-imidazoles and related compounds.
AID59395Minimal effective dose that resulted in significant reduction in PVC frequency in conscious dogs by po administration after 24 hours of coronary artery ligation1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
AID1130761Antiarrhythmic activity in New Zealand rabbit left atrium assessed as reduction in maximum following frequency (MFF)1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Antiarrhythmic activity of some N-alkylbispidinebenzamides.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID692194Inhibition of human OCT1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID142350Muscarinic acetylcholine receptor binding affinity in rat brain homogenate by [3H]quinuclidinylbenzilate displacement compared to disopyramide.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: 4,4-disubstituted hexahydro-3H-pyrido[1,2-c]pyrimidin-3-ones and related compounds.
AID142354Ratio of Muscarinic acetylcholine receptor affinity (IC50) of test compound to that of disopyramide1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: monobasic derivatives of disobutamide.
AID235407Therapeutic ratio in mixed-breed or Beagle dogs after intravenous administration of the compound.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID129483Inhibition of chloroform induced ventricular arrhythmia1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346751Human Kv11.1 (Voltage-gated potassium channels)2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,515)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990968 (63.89)18.7374
1990's336 (22.18)18.2507
2000's129 (8.51)29.6817
2010's63 (4.16)24.3611
2020's19 (1.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.93 (24.57)
Research Supply Index7.53 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index111.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials206 (12.42%)5.53%
Reviews120 (7.23%)6.00%
Case Studies245 (14.77%)4.05%
Observational1 (0.06%)0.25%
Other1,087 (65.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacological Strategy After 12 Months Follow-up. [NCT02294955]152 participants (Actual)Interventional2008-05-31Active, not recruiting
[NCT00000556]Phase 30 participants Interventional1995-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]